Products
Xaluritamig Biosimilar Bispecific Antibody (STEAP1 × CD3) for Research
Cat No.: GMP-Bios-INN-1467
Anti-STEAP1 therapeutic antibody (Pre-made Xaluritamig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Xaluritamig (development code AMG-509) is a bispecific antibody targeting STEAP1 and CD3. It is developed by Amgen and Xencor and BeiGene for Prostate cancer, Ewing's sarcoma in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1467-1mg | 1mg | |
| GMP-Bios-INN-1467-10mg | 10mg | |
| GMP-Bios-INN-1467-100mg | 100mg | |
| GMP-Bios-INN-1467-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Xaluritamig biosimilar, Bispecific Mixed mAb and scFv, Anti-STEAP1;CD3 Antibody: Anti-STEAP1/STEAP1 protein/Six-transmembrane epithelial antigen of prostate 1/STEAP therapeutic antibody |
| INN Name | Xaluritamig |
| Target | STEAP1;CD3 |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 8ucd:HL;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Amgen;Xencor;BeiGene |
| Conditions Approved | na |
| Conditions Active | Prostate cancer;Ewing's sarcoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
